HALP Score and Albumin Levels in Men with Prostate Cancer and Benign
Prostate Hyperplasia
Abstract
Aims: To evaluate the diagnostic significance of the novel index
combining preoperative hemoglobin, albumin levels, lymphocyte and
platelet counts (HALP) in prostate cancer (PCa) patients. Methods:
Between January 1, 2015 to December 31, 2018 at the Hitit University
Erol Olçok Education and Research Hospital 225 patients who had
undergone transrectal ultrasound guided prostate biopsy or prostate
surgery were analyzed retrospectively. A total of patients; 155 had
benign prostate hyperplasia (group 1) and 70 had PCa (group 2). The
preoperative serum levels of hemoglobin, albumin, lymphocyte counts, and
platelet counts were recorded. The HALP scores and the sub parameters of
this index for each of the two groups were compared. Results: The total
Prostate Specific Antigen (PSA), albumin and lymphocyte differences
between the groups were statistically significant (p=0.0002, p=0.0001,
p= 0.005). The median value of HALP scores in Group 1 and 2 were 49.43
and 51.2 respectively, and this was not statistically significant
between groups (p=0.737). The HALP score had the least Area Under Curve
(AUC) value compared to the others (0.514). the AUC of Albumin was
larger than PSA for diagnostic efficacy in PCa patients (0.696-0.656).
However, albumin levels were statistically significant compared to
platelet count and the HALP score (p=0.0033, p=0.0068), except PSA and
lymphocyte (p=0.4580, p=0.1717). Conclusion:Further prospective clinical
studies that include more patients from multiple centers are needed to
show the diagnostic role of the HALP score and its compounds on the
patients with PCa.